Beam Therapeutics Inc.

Beam Therapeutics Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, dedicated to developing precision genetic medicines. The company's core mission is to provide lifelong cures for serious diseases by leveraging its proprietary base editing technology.

Beam Therapeutics' innovative approach centers on base editing, a gene-editing technique that enables precise single-base changes in DNA without creating double-stranded breaks, a key differentiator from other gene-editing methods. The company is advancing a diversified pipeline of programs, including risto-cel (formerly BEAM-101) for severe sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-301 for glycogen storage disease type 1a, and BEAM-304 for phenylketonuria. They also have an Engineered Stem Cell Antibody Paired Evasion (ESCAPE) conditioning platform.

Led by CEO John Evans, Beam Therapeutics is positioned at the forefront of genetic medicine. Recent notable developments include the publication of BEACON Phase 1/2 data for risto-cel in The New England Journal of Medicine and the granting of Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA for BEAM-101. The company also reported its fourth quarter and full-year 2025 financial results and announced the initiation of a new liver-targeted program, BEAM-304. Beam Therapeutics maintains a robust financial position to support its ongoing research and development efforts.